Objective: Renal failure after bypass is still a threatening problem prolonging hospital care and reducing overall survival. The following pilot study was aimed to analyze whether perioperative low-dose prostacyclin infusion is able to preserve renal function in a selected group of patients who according to a poor cardiac function were stratified as high risk for the development of renal failure after bypass.
P ostoperative renal dysfunction is a challenging problem in cardiac bypass surgery. The incidence of oliguric acute renal failure requiring dialysis after cardiopulmonary bypass is reported to range between 1% and 5% (1) (2) (3) (4) and the number of patients with mild degrees of azotemia not requiring dialysis reaches even up to 30% (1, 2) .
In recent years it became obvious that postoperative renal dysfunction and failure does not merely represent an inconvenient complication prolonging intensive care treatment and hospitalization, but that acute renal failure (ARF) may directly contribute to the risk of death (1, 5, 6) . Mangano et al. (1) in a prospective multicenter study including 2,222 pa-tients found that the in-hospital mortality rate among all patients with renal dysfunction was 27%, representing 70% of all deaths from any causes in the entire study sample. In contrast, only 0.9% of patients without postoperative renal dysfunction died. Discharges to extended care or rehabilitation facilities were two to five times more frequent for patients with renal failure and for patients with renal dysfunction not requiring dialysis. Chertow et al. (3) in a prospective cohort study including 43,642 coronary bypass or valvular heart surgery patients found that the 30-day mortality in patients with ARF was 63.7%, compared with 4.3% in patients without ARF.
The etiology of renal dysfunction after cardiac surgery is multifactorial and, as we know today, not limited to perioperative complications alone. Chattas et al. (7) found a surprisingly high incidence of ARF after cardiopulmonary bypass (CPB) in the absence of severe perioperative cardiovascular failure or toxic insults to the kidney. A variety of different factors like nonpulsatile blood flow during cardiopul-monary bypass, increased levels of circulating catecholamines (8) , or the induction of inflammatory mediators may in concert precipitate profound physiologic perturbations leading to renal ischemia or hypoxia. Especially older patients, patients with severe heart failure, diabetics, and patients with preexisting renal insufficiency are particularly vulnerable to bypass renal dysfunction or failure after bypass (1, 3) .
Hypoxic or ischemic injuries to vital organs not only damage parenchymal cells but also affect the function and reactivity of the vasculature serving these organs (9) . A general feature of this vascular alteration is an augmented sensitivity to vasoconstrictor stimuli prolonging the period of ischemic insult and increasing the vulnerability to additional ischemic attacks. An explanation for the augmented vasoconstrictor sensitivity has been found in an attenuated vasculare response to the nitric oxide (NO) system (10, 11) . Mediators that exert their vasodilatory via NO-system fail to achieve a sufficient vasodilatation. In these circum-stances, an appropriate vasodilatory response can only be achieved by NOindependent mediators (9, 12, 13) . Prostacyclin is considered to be such an NO-independent mediator. It is produced by the cyclooxygenase pathway and plays a major physiologic role as a potent mediator of vasodilatation and reversible inhibitor of platelet aggregation (9, 14) . In addition, prostacyclin exerts important cytoprotective properties facilitating tissue repair and preventing polymorphonuclear leukocyte activation and migration into tissue (15, 16) .
In healthy volunteers, low-dose prostacyclin has proven to exert beneficial effects on renal and systemic hemodynamics as well as on tubular function (14) . So far, no data are available about the impact of prostacyclin in high-risk patients after cardiopulmonary bypass surgery.
The aim of this study was to investigate whether low-dose prostacyclin is able to preserve renal function during and after cardiopulmonary bypass surgery in a highly selected group of patients who according to their poor cardiac function (ejection fraction Ͻ40%) were stratified as high-risk for postoperative renal dysfunction (1, 3) .
MATERIALS AND METHODS
Study Population. The study was approved by the local ethics committee and is in accordance with the Declaration of Helsinki. Thirtyfour patients scheduled for primary elective coronary bypass surgery were studied prospectively. After giving their informed consent, patients were randomized to prostacyclin treatment (n ϭ 17) or the control group (n ϭ 17). Criteria for inclusion were poor left ventricular function, ejection fraction Ͻ40% as assessed by left ventricular angiography, stable renal function (creatinine Ͻ150 mol/L) and age Ͻ80 yrs. Because of their poor cardiac function, all patients were stratified as high risk for the development of renal dysfunction after bypass (1, 3) . Patients with concomitant valve or left ventricular reducing operations (Batista operation) as well as cardiac redo operations were excluded from the study to minimize bleeding complications caused by prostacyclin. None of the patients had been exposed recently to nephrotoxic drugs. Time interval between cardiac catheterization (angiographic contrast material administration) and surgery was 42.2 Ϯ 30.5 days for the prostacyclin and 52.2 Ϯ 44.4 days for the control group (not significant [NS]).
Patients Management. Patients were premedicated with 7.5 mg midazolam orally. Anesthesia was induced with sufentanil 1.5-2 g/kg/hr, midazolam 1-3 mg, etomidate 10 -18 mg, as well as pancuronium 0.2 mg/kg and maintained with sufentanil 0.7-1.5 g/kg/ hr, midazolam 1-1.5 mg/hr, and pancuronium 0.07-0.1 mg/kg/hr. All patients received cefotiam (2 g), a second-generation cephalosporin immediately before surgery.
Cardiac monitoring consisted of radial arterial pressure and thermodilution pulmonary artery catheter. Urine output was monitored by indwelling bladder catheter.
Nonpulsatile extracorporeal circulation was performed with a roller pump and a microporous hollow fiber membrane oxygenator (CAPRIOX 18) primed with 1.5 L of a solution containing as main components 500 mL Ringer's solution, 500 mL of hydroxyethyl starch 6%, 200 mL mannitol, 1 g methylprednisolone, aprotinin, and heparin 8000 IU. Pump flow was 2.5 L/min/m 2 . During bypass, mean arterial pressure was maintained between 80 and 100 mm Hg and body temperature was kept constant between 34 and 36.5°C.
Prostacyclin (Flolan, Glaxo-Wellcome, London, UK) was added to the standard protocol in a dosage of 2 ng/kg/min starting immediately after anesthesia. Prostacyclin infusion was continuously given throughout the intervention and was continued on the intensive care ward for a maximum of 48 hrs.
Duration of surgery, CPB time, crossclamp time, central venous pressure, mean arterial pressure, blood loss, hematocrit, and the amount of administered diuretics and catecholamines were documented.
Laboratory Procedures. Plasma and urinary electrolytes, osmolarity and creatinine were measured before surgery (baseline) and 6, 24, and 48 hrs postoperatively. From these data, the fractional excretion of sodium and the endogenous creatinine clearances (CCr) were calculated. Clearances were calculated according to the standard clearances formula: C ϭ (U*V)/(P*t) expressed per 1.73 m 2 body surface area; where V is urine volume, U and P urine and plasma creatinine concentration, and t is the time in mins, respectively. Endogenous creatinine clearance was taken for characterization of the glomerular filtration rate (GFR). Fractional excretion of sodium (FE Na ) was calculated as C Na /GFR * 100.
Urine concentration of N-acetyl-␤-Dglucosaminidase (␤-NAG) and ␣1-macroglobulin were measured at the above-mentioned time points as markers for tubular damage. Microalbumin was measured as marker for glomerular damage. Creatinine, urea, sodium, and potassium in plasma and urine were measured by creatininase, urease (Boehringer, Mannheim, Germany), or iron-selective electrodes on a Hitachi 747. Albumin and ␣1macroglobulin were measured by immunoturbidimetry (Tinaquant, Boehringer) on a Hitachi 717. ␤-NAG were measured by cresolsulfonphthaleinyl derivate at 37°C (end point method) on PCP (Eppendorf, Germany). Osmolarity was cryoscopically determined by Osmomat 030-D (Gonotec, Berlin, Germany).
Plasma aldosterone was estimated by a commercial direct radioimmunoassay (Biochem Immunosystems, Freiburg, Germany) using a double-antibody magnetic separation technique. The antialdosterone antibody (polyclonal, rabbit) showed cross-reactivity with 5␣-dihydroaldosterone (14.1%) and with 5␣-5␤-tetrahydroaldosterone (1.1%), whereas all other steroids cross-reacted at a level lower than 0.0001%. The limit of assay was estimated to be 16.6 pmol/L. The intra-assay coefficient of variation was 3.5% to 5.4% for values between 244 and 3803 pmol/L; the intra-assay coefficient was 3.6% to 6.4%. The normal values in supine position were found to be between 33 and 420 pmol/L and in upright position between 195 and 970 pmol/L. Plasma renin was determined by a commercial immunoradiometric assay (RENIN III Generation PASTEUR, Sanofi Diagnostics, Pasteur Marnes la Coquette, France) using two monoclonal complementary antibodies in a sandwich technique. The lowest detectable level of active renin has been found under 1 pg/mL. 
RESULTS
Thirty-four patients were recruited to the study and randomized either to the prostacyclin or the control group. Groups did not differ with regard to age, gender, comorbidity, and cardiac performance before operation (Table 1) .
Prostacyclin infusion was well tolerated in all patients and no sight effects were observed. Bleeding complications or relevant hypotensive episodes resulting from prostacyclin infusion did not occur. Mean duration of prostacyclin infusion was 26 Ϯ 9 hrs (range, 16 -48 hrs).
Two patients, one in the prostacyclin and one in the control group developed postoperative acute renal failure necessitating hemofiltration therapy. Both patients were accurately monitored according to the study protocol but were excluded from further statistical analysis to prevent distortion of the overall results. The first patient (prostacyclin group) was a 66-yr-old male with a noninsulin-dependent diabetes, cardiac ejection fraction was 21%. He received three coronary artery bypass grafts and operation time was 285 min. He developed a severe systemic inflammatory response syndrome immediately after surgery and died after 28 days as a result of septic multiorgan failure. The second patient (control group) was a 77-yr-old female with a noninsulin-dependent diabetes. She received four coronary artery bypass grafts and operation time was 205 min without severe hypotensive episodes. She developed an oliguric ARF that recovered well after 5 days. She left the intensive care unit for an extended care facility on day 7 after surgery.
In the prostacyclin treated group, two patients experienced an increase Ն25% from their baseline creatinine values at 6 hrs after CBP compared with five patients in the control group. At 24 hrs, the num-ber of patients increased to five in the prostacyclin group and eight in the control group.
Clinical characteristics of the study population during surgery are given in Table 2 . Duration of operation, CPB, and cross-clamp time did not differ between both groups. Mean arterial pressure, central venous pressure, and hematocrit remained stable. Urine output was comparable in both groups. Apart from low-dose dopamine, no additional catecholamines were given and no diuretics were applied.
Significant differences in the course of the CCr between the prostacyclin and the control group were observed. CCr before intervention was 91 Ϯ 5 mL/min (mean Ϯ SEM) in the prostacyclin and 100 Ϯ 6 mL/min in the control group (NS). Whereas follow-up values remained almost stable in the prostacyclin group, values in the control group showed a significant decline with a prolonged recovery period (Fig. 1) . At 6 hrs, paired analyses revealed a nonsignificant decline from baseline values to 84 Ϯ 7 mL/min in the prostacyclin group but a highly significant drop to 64 Ϯ 9 mL/min in the control group (p Ͻ .01) ( Fig. 1) .
Mean CCr values at 24 hrs differed significantly between both groups (p Ͻ .01) and even values at 48 hrs postoperative were still in favor for the prostacyclin group. In parallel, urine production in the treatment group was significantly higher (Fig. 2) although there were no differences in mean arterial pressure, central venous pressure, and the amount of diuretics used (Table 3 ). Fractional excretion of sodium showed a substantial increase at 6 hrs in the control group (p Ͻ .05), whereas in the prostacyclin treatment group values remained almost stable (Table 4 ). Twenty-four hours after CBP FE Na turned back to baseline in both groups. We found no difference in the ␤-NAG urine excretion between both groups. Baseline and 6-hr values are shown in Table 4 . Values at 24 hrs were 101 Ϯ 20 nmol/sec/L vs. 114 Ϯ 20 nmol/ sec/L (mean Ϯ SD), respectively (NS). Urine osmolarity did not differ throughout the observation period in both groups. Osmolarity at 6 hrs was 464 Ϯ 27 mosmol/kg in the prostacyclin group and No differences were found for cardiovascular hemodynamics during surgery and in the follow-up period. Cardiac index (L/min/m 2 ) before surgery was 2.0 Ϯ 0.6 for the prostacyclin group and 2.5 Ϯ 0.7 for the control group (NS). Values at the end of CBP were 2.8 Ϯ 0.8 and 3.4 Ϯ 0.9 respectively (NS). Twelve hours after surgery values were 3.0 Ϯ 0.7 vs. 2.8 Ϯ 0.7 (NS).
Hypotensive episodes (defined as period with a systolic blood pressure Ͻ100 mm Hg given in minutes) during surgery were comparable between both groups. Values were 49.2 Ϯ 62.2 min in the prostacyclin and 43.8 Ϯ 33.4 in the control group (NS). In all circumstances, hypotension was controlled, no episode of unexpected hypotensive crisis occurred, and no vasopressive agents apart from dopamine was necessary. In the first 6 hrs after surgery, 12 patients from the prostacyclin group experienced hypotensive episodes (mean duration of 18. Time on the intensive care ward was similar in both groups-25.1 Ϯ 7.7 hrs for the prostacyclin group and 24.7 Ϯ 7.5 for the control group.
DISCUSSION
Our study was conducted to evaluate the effect of low-dose prostacyclin on renal function after CPB. Prostacyclin was added to the "standard" anesthesiological protocol. Patients who according to their poor cardiac function were stratified as high risk for the development of renal dysfunction after bypass were selected for this study. We found a significant difference in the postoperative course of CCr and urine output between the prostacyclin and the control group in favor for the prostacyclin-treated group.
Despite improved operative mortality, renal dysfunction after bypass remains a relevant problem in CPB surgery. Complications of acute renal failure like volume overload, metabolic derangements (17, 18) , amino acid depletion (19, 20) , or uremic induced immune dysfunctions (21) can severely jeopardize patients' convalescence, prolonging intensive care treatment and hospitalization. As we know today, even moderate forms of acute renal failure not requiring renal replacement therapies are associated with increased death rates (6) . Morbidity and mortality even increases once dialysis is required (1, 2, 3, 5) . Proinflammatory effects of membrane bioincompatibility (22) , complement activation (23), loss of water-soluble vitamins (24), selenium depletion (25) , bleeding, or infections during catheterization are only some aspects of a long list of pathologies that may negatively affect the course of a multiple organ failure during dialysis or hemofiltration contributing to the increased risk of death.
Prostacyclin has proven to exert beneficial effects in experimental animal model of acute renal failure preserving renal function and facilitating tissue repair (15, 16, 26 -29) . Its beneficial effects reach far beyond simple vasodilation. Prostaglandins have been shown to improve GFR without any effect on renal blood flow suggesting a nonhemodynamic action to limit injury (30) . Such a cytoprotective phenomenon seems to be generalized inasmuch as it has also been demonstrated in gastrointestinal epithelium where they enhance mucosal repair by increasing intracellular cAMP and Ca 2ϩ , which in turn signals cytoskeletal- mediated tight junction closure (16) . Moreover inhibition of leukocyte activation by prostacyclin seems to play a crucial role, too (31, 32) . Activated leukocytes adhered to endothelial cells can damage the endothelial lining through the release of neutrophil elastase (33), increasing microvascular permeability.
In gastric tissue, prostacyclin has been shown to inhibit reduction of gastric mucosal blood flow by inhibiting neutrophil activation under stress conditions (34) .
In experimental ischemic myocardial injury, the reduction in circulating neutrophils significantly reduced the extent of tissue damage interpreted by the authors as a result of the inhibition of oxygenderived free radical formation from neutrophils (35) . Prostacyclin is a potent inhibitor of platelet aggregation and adhesion by binding to specific platelet receptors thus regulating plug formation and platelet deposition on vascular surfaces (36 -38) . Prostacyclin also seems to exert anti-inflammatory properties by selectively inhibiting the release of proinflammatory cytokines from human peripheral blood mononuclear cells (39, 40) . In the kidney, prostacyclin is thought to be stimulated by a decrease in glomerular perfusion pressure in parallel with an increase in renin secretion (41, 42) . A prominent expression of the prostacyclin receptor has been found in renal endothelial cells, glomeruli, and smooth muscle cells of interlobular arteries, afferent arterioles, and small veins (43), indicating that the kidney is a key organ for prostacyclin activity. Nielsen et al. (14) studied the effect of different doses of intravenous prostacyclin (2, 4, and 8 ng·kg Ϫ1 ·min Ϫ1 ) infusion on renal and systemic hemodynamics as well as on renal tubular function in 13 healthy volunteers. Prostacyclin led to a significant in-crease in renal plasma flow at doses of 4 and 8 ng·kg Ϫ1 ·min Ϫ1 , with a slight but significant decline in mean arterial pressure and rise in heart rate. No effects on GFR and renal tubular handling of sodium and water were observed. At 2 ng·kg Ϫ1 ·min Ϫ1 , renal plasma flow increased from 504 mL·min Ϫ1 to 540 mL·min Ϫ1 (NS), GFR was not affected. These data are consistent with findings made in other human studies or animal models (9, 44) .
Until now, no data are available on renal hemodynamic effects of low-dose prostacyclin in high-risk patients after CPB. In this pilot study, we were able to demonstrate that low-dose prostacyclin administration is able to preserve renal function in patients with poor cardiac function. During CPB, GFR is known to decline but usually turns to baseline levels postoperatively (45) (46) (47) . Although CPB time and cross-clamp time tended to be longer in the prostacyclin group, these patients maintained stable GFR values throughout the observation period whereas the nontreated group experienced a highly significant decline in their GFR with a subsequent prolonged recovery phase. In parallel, urine production was significantly higher in the prostacyclin-treated group although there was no statistical difference in central venous pressure, mean arterial pressure, and the amount of diuretics given between both groups. An explanation for our findings could be that low-dose prostacyclin is able to maintain an adequate renal blood flow throughout the critical perioperative period, preventing vasoconstriction and thus protecting the kidney from episodes of ischemia or hypoxia. Tubular function also seems to be positively affected by prostacyclin infusion. FE Na showed a steeper increase at 6 hrs in the control group compared with the prostacyclin group. FE Na turned to normal after 24 -48 hrs in both groups. Tubular necrosis or glomerular damage did not seem to be a relevant problem in our study population. ␤-NAG, a specific enzyme for tubular necrosis, did not increase in either the prostacyclin or in the control group. Microalbumin, a marker for increased glomerular permeability, was not increased and did not differ between groups. Analyses of renin and aldosterone showed no statistical difference between groups. We found an increase in aldosterone levels at 6 hrs after CPB in both groups postoperatively. Because there is an increasing number of patients with a high risk for the development of renal dysfunction after bypass, strategies for preventing postoperative renal dysfunction are needed. This becomes even more important as new evidence indicate that even mild forms of renal failure not requiring dialysis are associated with increased mortality rates (6) . Despite the small number of patients included in this study, evidence is provided indicating that continuous perioperative low-dose prostacyclin infusion can be useful in preserving renal function in high-risk patients. Prostacyclin applied in a dose of 2 ng/kg/min does not seem to be associated with increased bleeding complications or threatening hypotensive episodes. Because of its short biological half-life time of only a few minutes, it can be easily handled without any danger of drug accumulation. Prospective, placebo-controlled follow-up studies with the inclusion of more patients are needed to evaluate whether perioperative low-dose prostacyclin has a beneficial impact on hospitalization and/or patient outcome. I n this pilot study, we were able to demonstrate that low-dose prostacyclin administration is able to preserve renal function in patients with poor cardiac function.
